Sulbactam/ampicillin versus cefotetan in the treatment of obstetric and gynecologic infections.

Abstract

In an open, randomized clinical study, the safety and efficacy of sulbactam/ampicillin was compared to that of cefotetan in 95 hospital patients with gynecologic or obstetric infections. Sulbactam/ampicillin (1 g:2 g), was administered intravenously every 8 h to 46 patients, and cefotetan (2 g) was administered intravenously every 12 h to 49 patients. All 23 patients with obstetric infections and 18 of the 23 patients with gynecologic infections treated with sulbactam/ampicillin were evaluated as cured. All 21 patients with obstetric infections and 23 of the 28 patients with gynecologic infections treated with cefotetan were evaluated as cured. No side effects requiring discontinuation of therapy or reduction of the dose administered, were observed.

• Authors: S Scalambrino, C Mangioni, R Milani, M Regallo, S Norchi, L Negri, S Carrera, E F Vigano, M P Ruffilli, M P Canale
• Journal: Supplement to International journal of gynecology and obstetrics (Suppl Int J Gynecol Obstet) Vol. 2 Pg. 21-7 ( 1989) ISSN: 0924-8447 [Print] Ireland
• PMID: 2679680 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Cefotetan
• Ampicillin
• Sulbactam

Topics

• Adult
• Aged
• Ampicillin (adverse effects, therapeutic use)
• Bacterial Infections (drug therapy, microbiology)
• Cefotetan (adverse effects, therapeutic use)
• Drug Therapy, Combination (adverse effects, therapeutic use)
• Female
• Genital Diseases, Female (drug therapy, microbiology)
• Humans
• Middle Aged
• Pregnancy
• Pregnancy Complications, Infectious (drug therapy, microbiology)
• Randomized Controlled Trials as Topic
• Sulbactam (adverse effects, therapeutic use)